Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 2/10

vs
industry
vs
history
Cash to Debt 0.91
NSPR's Cash to Debt is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 0.91 )
NSPR' s 10-Year Cash to Debt Range
Min: 0.34   Max: No Debt
Current: 0.91

Equity to Asset -0.20
NSPR's Equity to Asset is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -0.20 )
NSPR' s 10-Year Equity to Asset Range
Min: -0.35   Max: 0.78
Current: -0.2

-0.35
0.78
F-Score: 2
Z-Score: -15.58
M-Score: -9.53
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -228.66
NSPR's Operating margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -228.66 )
NSPR' s 10-Year Operating margin (%) Range
Min: -228.66   Max: -228.66
Current: -228.66

Net-margin (%) -244.25
NSPR's Net-margin (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -244.25 )
NSPR' s 10-Year Net-margin (%) Range
Min: -244.25   Max: -244.25
Current: -244.25

ROE (%) -217.13
NSPR's ROE (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -217.13 )
NSPR' s 10-Year ROE (%) Range
Min: -217.13   Max: -200
Current: -217.13

-217.13
-200
ROA (%) -140.13
NSPR's ROA (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -140.13 )
NSPR' s 10-Year ROA (%) Range
Min: -400   Max: -80
Current: -140.13

-400
-80
ROC (Joel Greenblatt) (%) -758.93
NSPR's ROC (Joel Greenblatt) (%) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: -758.93 )
NSPR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -758.93   Max: -758.93
Current: -758.93

» NSPR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with NSPR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 10.57
NSPR's P/S is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 10.57 )
NSPR' s 10-Year P/S Range
Min: 7.96   Max: 54
Current: 10.57

7.96
54
Current Ratio 1.27
NSPR's Current Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 1.27 )
NSPR' s 10-Year Current Ratio Range
Min: 0.13   Max: 4.68
Current: 1.27

0.13
4.68
Quick Ratio 1.11
NSPR's Quick Ratio is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 1.11 )
NSPR' s 10-Year Quick Ratio Range
Min: 0.13   Max: 4.28
Current: 1.11

0.13
4.28

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.50
NSPR's Price/Median PS Value is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. NSPR: 1.50 )
NSPR' s 10-Year Price/Median PS Value Range
Min: 0.54   Max: 2.98
Current: 1.5

0.54
2.98

Business Description

Industry: »
Compare: » details
InspireMD, Inc. was organized in the State of Delaware on February 29, 2008 as Saguaro Resources, Inc. to engage in the acquisition, exploration and development of natural resource properties. On March 28, 2011, it effectuated a 1-for-3 forward stock split and changed its name from 'Saguaro Resources, Inc.' to 'InspireMD, Inc.' It is an innovative medical device company focusing on the development and commercialization of its proprietary stent platform technology, MGuard. MGuard provides embolic protection in stenting procedures by placing a micron mesh sleeve over a stent. The Company's initial products are marketed for use mainly in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). According to the TYPHOON STEMI trial and the SOS SVG Trial of patients with acute myocardial infarction and saphenous vein graft coronary interventions, 7.5% to 44% experience major adverse cardiac events, including cardiac death, heart attack, and restenting of the artery. When performing stenting procedures in patients with acute coronary symptoms, interventional cardiologists face a difficult dilemma in choosing between bare-metal stents, which have a high rate of restenosis (formation of new blockages), and drug-eluting (drug-coated) stents, which have a high rate of late thrombosis (formation of clots months or years after implantation), require administration of anti-platelet drugs for at least one year post procedure, are more costly than bare-metal stents and have additional side effects. It intends to use its MGuard technology in a broad range of coronary related situations in which complex lesions are required and make it an industry standard for treatment of acute coronary syndromes. It also intends to apply its technology to develop additional products used for other vascular procedures, specifically carotid (the arteries that supply blood to the brain) and peripheral (other arteries) procedures. The Company markets its products through distributers in international markets, mainly in Europe and Latin America.
» More Articles for NSPR

Headlines

Articles On GuruFocus.com
InspireMD Reports 4 Significant Insider Buys Apr 19 2013 

More From Other Websites
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Aug 11 2014
InspireMD to Announce Results of CGuard™CARENET Trial at the TCT Innovation Session on Late... Aug 11 2014
InspireMD to Announce Results of CGuard™ CARENET Trial at the TCT Innovation Session on Late... Aug 11 2014
INSPIREMD, INC. Files SEC form 10-Q, Quarterly Report Aug 04 2014
INSPIREMD, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Jul 24 2014
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014 Jul 23 2014
InspireMD Reports Financial Results for the Second Quarter Ended June 30, 2014 Jul 23 2014
INSPIREMD, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events,... Jul 18 2014
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July... Jul 17 2014
InspireMD to Report Financial Results for the Second Quarter Ended June 30, 2014 on Wednesday, July... Jul 17 2014
InspireMD appoints James Barry as COO Jul 15 2014
InspireMD Appoints Dr. James Barry as Chief Operating Officer Jul 15 2014
InspireMD Appoints Dr. James Barry as Chief Operating Officer Jul 15 2014
InspireMD Announces Successful Completion of CGuardTM CARENET (CARotid Embolic protection study... Jul 08 2014
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 08 2014
InspireMD Announces Successful Completion of CGuard™ CARENET (CARotid Embolic protection study... Jul 08 2014
InspireMD Selected for Inclusion in the Russell Microcap Index Jul 03 2014
InspireMD Selected for Inclusion in the Russell Microcap® Index Jul 01 2014
INSPIREMD, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 23 2014
InspireMD receives European approval to resume MGuard Prime manufacturing Jun 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK